drugset
Drugs / IGIV3I
last change Nov 2018 re-read 3 minutes ago

IGIV3I

also known as Flebogamma 10% DIF

Protein / enzyme biologic

Developed for
autoimmune thrombocytopenic purpura
Investigated by
Grifols Biologicals, LLC · Grifols, S.A.

Trials 1

today NCT00511147 · Ph 3
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00511147 May 2008 → Apr 2014 autoimmune thrombocytopenic purpura Grifols Biologicals, LLC Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as IGIV3I ClinicalTrials.gov intervention name — accepted as the source's own label NCT00511147 ↗
Known as Flebogamma 10% DIF “10% intravenous immunoglobulin (IVIG; Flebogamma® 10% DIF)” PMID 30499734 ↗ Nov 2018
Modality Protein / enzyme biologic “10% intravenous immunoglobulin (IVIG; Flebogamma® 10% DIF)” PMID 30499734 ↗ Nov 2018
Route Intravenous “10% intravenous immunoglobulin (IVIG; Flebogamma® 10% DIF)” PMID 30499734 ↗ Nov 2018